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Abstract
Objective To describe the training undertaken by pharmacists employed in a
pharmacist-led information technology-based intervention study to reduce medica-
tion errors in primary care (PINCER Trial), evaluate pharmacists’ assessment of the
training, and the time implications of undertaking the training.
Methods Six pharmacists received training, which included training on root cause
analysis and educational outreach, to enable them to deliver the PINCER Trial inter-
vention. This was evaluated using self-report questionnaires at the end of each train-
ing session. The time taken to complete each session was recorded. Data from the
evaluation forms were entered onto a Microsoft Excel spreadsheet, independently
checked and the summary of results further verified. Frequencies were calculated for
responses to the three-point Likert scale questions. Free-text comments from the
evaluation forms and pharmacists’ diaries were analysed thematically.
Key findings All six pharmacists received 22 h of training over five sessions. In four
out of the five sessions, the pharmacists who completed an evaluation form (27 out
of 30 were completed) stated they were satisfied or very satisfied with the various ele-
ments of the training package. Analysis of free-text comments and the pharmacists’
diaries showed that the principles of root cause analysis and educational outreach
were viewed as useful tools to help pharmacists conduct pharmaceutical interven-
tions in both the study and other pharmacy roles that they undertook. The opportu-
nity to undertake role play was a valuable part of the training received.
Conclusions Findings presented in this paper suggest that providing the PINCER
pharmacists with training in root cause analysis and educational outreach contrib-
uted to the successful delivery of PINCER interventions and could potentially be uti-
lised by other pharmacists based in general practice to deliver pharmaceutical
interventions to improve patient safety.
Introduction
Studies have shown that medication errors, particularly those
relating to prescribing errors or insufficient medication
monitoring, are often a cause for potentially avoidable mor-
bidity and mortality in primary[1,2] and secondary care.[3]
With the majority of prescribing taking place in primary care,
pharmacists working in general practices are well placed
to identify and address these types of medication error,
although the evidence for their effectiveness has been
conflicting.[4–6]
However, more recently the results of the PINCER Trial,
a large cluster randomised controlled trial, demonstrated
that a complex pharmacist-led information technology-
based intervention resulted in significantly reduced rates of
clinically important and common medication errors within
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the primary care setting, compared with simple feedback.[7]
This was a parallel-group, pragmatic, cluster trial in which 72
general practices in England were randomised to either (1)
computer-generated feedback (‘simple feedback’) in which
practices were asked to make changes to patients’ medication
in a 12 week period or (2) the pharmacist-led intervention
comprising computer-generated feedback and dedicated
pharmacist support over a 12 week period. Quest Browser
software was used to search general practice computer
systems to identify patients at risk of harm associated with
10 specific pharmaceutical indicators (outcomes) (Table 1).
These pharmaceutical indicators (outcomes) were chosen
because they are consistently associated with the most
common medication errors resulting in serious morbidity,[8]
and were detectable from general practice computer systems.
In this paper we describe the training package undertaken
by pharmacists employed in the PINCER Trial and how train-
ing in the concepts of educational outreach and root cause
analysis (RCA) was used to help the pharmacists deliver the
intervention used in the trial. The paper also provides an
evaluation of the pharmacists’ responses to the training
package and discusses the time implications involved.
The role of the PINCER Trial pharmacist
The PINCER Trial pharmacists were responsible for deliver-
ing all aspects of the intervention, including presenting the
results of the computer-based searches to the general practi-
tioners (GPs) and their practice staff, resolving medication
errors in individual patients, identifying the underlying
causes of these medication errors and helping the practice
to implement new medicines management systems to avoid
future errors. It was therefore imperative that the pharma-
cists were effective at intervening, delivering and promoting
change.
To achieve this, the pharmacists were expected to build
relationships with GPs and other practice staff, and the
importance of fostering good relations was emphasised
throughout the training programme. A major focus of the
pharmacist intervention within each practice was a feedback
session where the pharmacist presented the results of the
Quest Browser searches, and used the principles of edu-
cational outreach and RCA to facilitate changes to the day-
to-day practice of healthcare professionals.
Educational outreach
Educational outreach (also known as educational visiting or
academic detailing) has been referred to as a face-to-face edu-
cational visit by a trained person to a healthcare professional
in their place of practice.[9] Educational outreach uses the
principles of social marketing and aims to build relation-
ships, meet needs, be convenient to the recipient and achieve
behaviour change in healthcare professionals.
Soumerai and Avorn have described the essential stages of
educational outreach as defining specific problems and
objectives, market research, establishing credibility, target-
ing ‘high potential’ clinicians, involvement of ‘opinion
leaders’, two-sided communication, promoting ‘active
learner’ involvement, repetition and reinforcement, brief
Table 1 PINCER Trial pharmaceutical indicators (outcomes)
Patients identified to be at risk from hazardous prescribing or inadequate monitoring Reason for inclusion
1 Patients with a computer-recorded history of peptic ulcer prescribed non-selective non-steroidal
anti-inflammatory drugs (NSAIDs) and no proton pump inhibitor (PPI) cover (Primary outcome)
Commonly occurring and
contraindicated by CSM
2 Patients with a computer-recorded diagnosis of asthma being prescribed a beta-blocker (Primary outcome) Contraindicated by CSM
2a Patients with a computer-recorded diagnosis of asthma (and no history of coronary heart disease (CHD)) being
prescribed a beta-blocker (Secondary outcome)
Contraindicated by CSM
3 Patients aged 75 years and older receiving long-term prescriptions for angiotensin-converting enzyme (ACE)
inhibitors or loop diuretics without a recorded assessment of renal function and electrolytes in the
preceding 15 months (Primary outcome)
Commonly occurring and
consensus of expert opinion
4 Patients on combined oral contraceptives with a past history of venous or arterial thrombo-embolism
(Secondary outcome)
Contraindicated by CSM
5 Patients stabilised on methotrexate therapy should have their full blood count (FBC) and liver function checked
every 12 weeks (Secondary outcome)
Risk highlighted by NPSA
6 Patients treated with warfarin should have their International Normalised Ratio (INR) monitored at least every
12 weeks (Secondary outcome)
Commonly occurring and
consensus of expert opinion
7 Patients on lithium therapy should have their lithium levels checked every 3 months (Secondary outcome) Consensus of expert opinion
8 Patients on amiodarone should have their thyroid function checked before starting amiodarone, and every
6 months during treatment (Secondary outcome)
Consensus of expert opinion
9 Prescriptions for methotrexate should specify a weekly dosing interval (Secondary outcome) Risk highlighted by NPSA
10 Patients prescribed amiodarone, should be on the lowest possible dose to avoid unnecessary toxicity
(Secondary outcome)
Consensus of expert opinion
CSM, Committee of Safety of Medicines; NPSA, National Patient Safety Agency.
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graphic materials and offering practical alternatives.[10] The
applications of the principles of educational outreach within
the PINCER Trial are described in Box 1.
The literature shows that educational outreach has been
used in a variety of healthcare settings to change professional
practice.[11–16] An updated Cochrane review, which included
69 studies involving more than 15 000 health professionals,
assessed the effect of educational outreach on health profes-
sional practice or patient outcomes. The authors concluded
that educational outreach alone, or when combined with
other interventions, had a relatively small but consistent posi-
tive effect on prescribing behaviour, but for other types of
professional practice, such as providing screening tests, edu-
cational outreach provided small to moderate changes in
practice, although the effects were varied.[9]
Root cause analysis
RCA is a retrospective, systematic review of an adverse inci-
dent that aims to identify what happened, how it happened
Box 1 The process of educational outreach in the PINCER Trial
Defining specific problems and objectives The specific problems to be discussed at the practice feedback session were
defined by the outcomes and by the patients identified in the computer
searches.
Market research The amount of market research that was undertaken was limited although
information was obtained on practice demographics, such as list size,
number of GPs and clinical system, to ensure the pharmacists had some a
priori knowledge of the practice in which they would be delivering the
intervention.
Establishing credibility Pharmacists were encouraged to introduce themselves at the start of the
feedback session and provide a brief summary of their professional
credibility by explaining their own background in clinical pharmacy and
their affiliation with either the University of Manchester or University of
Nottingham.
Targeting ‘high potential’ physicians Pharmacists were asked to identify one individual in the practice with whom
they could work closely while implementing changes. In effect, this person
could be a ‘high potential physician’ or a senior member of the practice
team.
Involvement of ‘opinion leaders’ The PINCER Trial was a high-profile study and the Chief Investigator was a
well respected GP and expert in medication error research. There were close
links with key stakeholders in the Primary Care Trusts involved in the trial
who helped champion the study.
Two-sided communication Pharmacists were encouraged to present a balanced argument for each
of the outcomes, giving reasons for and against changing practice. This
helped the pharmacists maintain credibility and be prepared for any
counter-arguments presented to them.
Promoting active learner involvement Pharmacists were encouraged to question the healthcare professionals about
their current clinical practice. This questioning aimed to identify know-
ledge gaps and attitudinal factors and stimulate learning.
Repetition and reinforcement Pharmacists were encouraged to end the feedback session by re-enforcing the
key findings from the computer searches and any action points agreed.
Brief graphic materials Evidence-based summaries were prepared for each pharmaceutical indicator
(outcome). These summaries provided information on the importance of
each type of error along with current guidelines for good clinical practice.
This information was given to a nominated member of the general practice
(usually the practice manager).
Offering practical alternatives Help was offered to take corrective action FOR individual patients with
medication errors.
Selection and training of academic
detailers
All pharmacists received the training as outlined in this paper.
Stacey Sadler et al. 49
© 2013 The Authors. IJPP © 2013 Royal Pharmaceutical Society International Journal of Pharmacy Practice 2014, 22, pp. 47–58
and why. The analysis is then used to identify areas for change,
and make recommendations for sustainable solutions to help
minimise the recurrence of the incident in future.[17] It
focuses on problems with the systems involved in adverse
events, not on people.
RCA has been used in the nuclear power and aviation
industries for a number of years to identify the underlying
cause of disasters. The National Patient Safety Agency
(NPSA) for England and Wales, the Joint Commissions on
the Accreditation of Healthcare Organisation in the USA and
the Queensland Health Patient Safety Centre and New South
Wales Health in Australia have all adopted the RCA process to
improve patient safety.[18,19] In 2007, the Royal Pharmaceuti-
cal Society issued a revised Clinical Governance Framework
for Pharmacist Prescribers.[20] One recommendation of the
framework was that ‘prescribing’ pharmacists should be con-
sidered in clinical risk management programmes, including
RCA.
There is evidence that RCA is being used to help investigate
the reasons behind critical incidents and medication errors
in a number of different healthcare settings.[21–25] However,
a recent review on RCA found that the literature on RCA
effectiveness was limited but provided anecdotal evidence
that RCA improved safety. The authors concluded that con-
trolled trials that tested the RCA framework, along with cost–
benefit analysis, were required to formally determine the
effectiveness of RCA.[26]
RCA uses a variety of tools and techniques through
different stages of investigation.[27] The application of the
principles of RCA in the PINCER Trial is described in
Box 2. Due to time limitations (the initial feedback session
usually lasted 1 h) it was not always possible to conduct all
stages.
The rationale for this paper is derived from the fact that
while health service literature describes either educational
outreach or RCA as a tool to change professional behaviour,
we believe that the PINCER Trial is the first time that key
principles from both tools have been used together for the
same aim. For this reason, we set out to document and evalu-
ate the training provided to the pharmacists to understand
which aspects of the training the pharmacists felt were helpful
in delivering the PINCER intervention, as these insights will
be crucial to allow for successful implementation outside the
setting of a trial.
Box 2. The process of root cause analysis in the PINCER Trial
Step 1: Identify the scope of the incident and
collect information
The specific incidents to be investigated were defined by the outcomes
of the PINCER Trial and patients were identified using Quest
Browser searches.
Step 2: Sort andmap data The data were presented as a series of tables in a Microsoft Excel
workbook and gave names of patients identified as being potentially
at risk for each of the outcomes.
Step 3: Problem identification and
prioritisation
During the feedback meeting a brainstorming session with GPs and
other practice staff was facilitated by the trial pharmacists to identify
the underlying reasons for the potentially hazardous prescribing and
medicines management issues.
Steps 4 and 5: Problem exploration and the
identification of safety and quality
improvements
GPs and other practice staff were encouraged by the pharmacists
to explore the issues identified in step 3 in greater detail using the
‘five whys’*, time permitting. This technique involves asking why
something happens until the ‘root cause’ has been identified. At
this stage of the process, the pharmacists helped the GPs and other
practice staff to identify changes within their day-to-day practice
which could help reduce the incidence of hazardous prescribing and
medicines management issues.
Step 6: Generating the root cause analysis
report, agreeing improvements for
implementation and shared learning
At the end of the feedback session the pharmacists were responsible for
summarising the key findings and agreeing an action plan stating
who would be responsible for making the necessary changes
discussed, along with timescales for delivery of the action plan.
*The five whys is a question technique that is used to explore the cause-and-effect relationships underlying a particular problem. By repeatedly
asking the question ‘why?’ the aim is to determine the root cause of a problem. Identifying the problem’s root cause may take fewer or more than
five ‘whys’ and will depend on the complexity of the issue, but usually five iterations of asking why is sufficient to identify the root cause. This
technique is often used as it is easy to learn and apply in practice and is a simple analysis tool as it can be completed without statistical analysis.[27]
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Methods
Ethical approval for the PINCER Trial was obtained from the
Nottingham 2 Research Ethics Committee (reference number
05/Q2404/26) on 15 March 2005.
Trial pharmacists
Six pharmacists were employed to deliver the intervention in
the PINCER Trial. The posts were advertised nationally.
Three of the pharmacists had previous experience of working
as primary care pharmacists, and the other three had limited
or no experience of working in a general practice setting,
having worked predominantly in community or secondary
care settings. Further details can be found in Table 2.
Training package
The training package was developed by the research team to
help the PINCER Trial pharmacists deliver the intervention.
The training sessions consisted of a combination of trial-
specific and generic elements. The trial-specific elements,
which were delivered by the research team, included a
general induction to the PINCER Trial, along with an intro-
duction to the pharmaceutical indicators (outcomes) used
in the PINCER Trial. The generic elements mainly com-
prised training on the concepts of RCA, educational out-
reach and role play for pharmacists to practise feeding back
results from the Quest Browser searches using the principles
of educational outreach and RCA. Further generic training
sessions on clinical coding, data quality and interpreting
practice data were delivered by a member of the Primary
Care Information Services (PRIMIS) team (www.primis.
nottingham.ac.uk) and, as such, were not tailored directly to
the needs of the PINCER Trial pharmacists. To maxi-
mise learning opportunities, a 30 min question-and-answer
session was provided at the start of each training day to give
the pharmacists the opportunity to ask questions arising
from the previous day’s training. In addition, a 1 h session
entitled ‘applying this to the PINCER Trial’ was held at
the end of each PRIMIS-led training session. Table 3 details
the topics covered in each of the five training sessions
held.
Four of the training sessions were held at the University of
Nottingham. The last training session was held in a Notting-
ham GP practice. Refreshments and lunch were provided for
each training session.
An evaluation form was included in the training session
packs, which were sent to the pharmacists prior to each train-
ing session. Pharmacists were asked to complete an evalua-
tion form immediately after each training session to inform
any future roll-out of the training package. The evaluation
forms were anonymous. The evaluation form sought to elicit
views on a number of factors such as the content and timing
of the pre-training material provided and the pace of train-
ing, the venue and their expectations of the training using a
three-point Likert scale. A copy of the evaluation form can be
found in Appendix 1. The pharmacists were also asked to keep
a reflective diary to capture their views on the training
package, along with their experiences of delivering the inter-
vention. The findings of delivering the intervention are
reported elsewhere.[28]
Data analysis
Data from the evaluation forms were entered onto a Micro-
soft Excel spreadsheet (Version 2003) by SR, independently
checked and the summary of results further verified by other
Table 2 Characteristics of the PINCER Trial pharmacists
Pharmacist
Age range at start
of training (years)*
Year of
registration Post-registration qualification(s)
Pharmacy background
at start of training*
Previous primary
care experience
1 25–30 After 2000 Diploma in community pharmacy Community† No
2 31–35 1995–2000 Diploma in community pharmacy Primary care†† Yes
3 31–35 1990–1994 Diploma in clinical pharmacy; Masters in
Public Health**
Primary care†† Yes
4 31–35 1995–2000 Diploma in clinical pharmacy; MSc
Clinical Pharmacy; PhD
Primary care†† Yes
5§ 40–45 1985–1989 Diploma in management studies Community† No
6 40–45 1985–1989 None Community† No
*July 2006.
**Was being undertaken at the start of the PINCER Trial.
†Community pharmacists are mainly, but not exclusively responsible for procurement, storage, dispensing, advising and distributing medicines (both
prescription and over the counter) in a community pharmacy setting.
††Primary care pharmacists work with GP/family practices on a whole range of issues related to prescribing, such as formulary development, ensuring
evidence-based prescribing practice, running specific clinics and providing education and advice on therapeutics.
§Pharmacy background predominantly in secondary care, had recently started working in community pharmacy at the start of the PINCER Trial.
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members of the research team (SS and RH). Frequencies were
calculated and presented as summary tables. Free-text com-
ments from the evaluation forms and the pharmacists’ diaries
were thematically coded and grouped according to emergent
themes.
Results
All six pharmacists received 22 h of training. This comprised
17 h and 15 min of generic training and 4 h and 45 min of
trial-specific training, provided over five training sessions.
The time allocated to the different components of the train-
ing sessions is shown in Table 3.
Twenty seven out of 30 (90%) evaluation forms were
completed. Details of the responses from the evaluation
forms for each of the training sessions can be found in
Table 4. It can be seen that in four out of the five training
sessions the pharmacists who completed an evaluation
form indicated that they were satisfied or very satisfied
with the various elements of the training package. The feed-
back was more positive for the training received on training
sessions one, four and five, which included training on
the concepts of RCA, educational outreach and the role-
play session. Training was deemed to be unsatisfactory
to one pharmacist on one occasion due to a noisy venue
and the pre-reading material not being sent in adequate
time.
Free-text comments from the evaluation forms and the
views recorded in the pharmacists’ diaries substantiated these
findings.
Pharmacists’ views on educational outreach
and RCA training
In training session 1 (where the concepts of educational out-
reach and RCA were taught) very positive comments from the
pharmacists were given:
Table 3 The PINCER Trial pharmacist intervention training programme
Training
session Topic Rationale for topic
Trial-specific or
generic training
Duration of
training
1 Introduction to PINCER Trial Understanding why the PINCER Trial was being undertaken
and the format of the intervention
Trial-specific 45 min
1 What is clinical research? To emphasise the importance of accurate data recording for
clinical trials
Generic 45 min
1 Introduction to pharmaceutical
indicators (outcomes)
Clinical and health service research evidence for why the 10
pharmaceutical indicators (outcomes) were chosen in the
PINCER Trial; an important facet of academic training
Trial-specific 1 h
1 Introduction to human error theory The use of RCA, one aspect of human error theory, would
help the pharmacist identify why system errors are
occurring in a GP practice
Generic 1 h 30 min
1 Introduction to educational outreach The use of educational outreach would help the pharmacist
deliver educational information to healthcare
professionals
Generic 1 h 30 min
2 Quality data and data outcomes Emphasise the importance of accurate data recording within
patient records, introduce the types of problems which
pharmacists might encounter and how to overcome them
Generic data analyst
training
3 h
2 System types Introduce the pharmacists to different general practice
systems
Generic data analyst
training
1 h
3 Clinical coding Help pharmacists understand clinical coding systems, how
mistakes can happen and how to avoid them
Generic data analyst
training
4 h 30 min
4 Data analysis, interpretation
and feedback
Help pharmacists to interpret practice data Generic data analyst
training
3 h
4 Role play Provide an opportunity for pharmacists to practise using the
principles of educational outreach and RCA
Generic 2 h
5 Introduction to Quest Browser Show the pharmacists how to access the data on the
pharmaceutical interventions (outcomes)
Trial-specific 45 min
5 Results of Quest Browser searches Help the pharmacists interpret the data outputs on the
pharmaceutical interventions (outcomes)
Trial-specific 1 h 15 min
5 Pharmacist record form Show the pharmacists how to complete forms which record
their activity within the practice during the intervention
period
Trial-specific 1 h
RCA, root cause analysis.
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An excellent day which has made me feel very excited
and positive about the job. (Pharmacist 2, evaluation
feedback for training session 1)
The content and delivery was excellent and the clinical
knowledge will benefit my work. (Pharmacist 1, evalu-
ation feedback for training session 1)
The main benefits cited from this training session were that
the concepts of educational outreach and RCA had increased
the pharmacists’ confidence at delivering key messages, along
with having the ability to use the concepts in their other phar-
macy posts:
Useful to learn about [educational outreach] and to
think about how you can use educational outreach
when delivering information to GPs, both in the trial
and in my other practice pharmacist job. (Pharmacist
4, diary extract regarding training session 1)
I feel more confident and competent in delivering key
messages. (Pharmacist 3, evaluation feedback for train-
ing session 1)
Pharmacists’ views on undertaking role play
The role play that the pharmacists undertook in training
session 4 was viewed positively and considered necessary to
successfully carry out the intervention:
Practising root cause analysis was very helpful. (Phar-
macist 5, evaluation feedback for training session 4)
Getting feedback on performance in role play was
helpful. (Pharmacist 2, evaluation feedback for train-
ing session 4)
One pharmacist in particular believed it was imperative
that pharmacists were given the opportunity to undertake
role play using the principles of RCA and educational out-
reach before using it on GPs:
It was quite daunting to have to do the role plays but
probably the most useful part of the training. . . . I
think we will need to have the opportunity to try and
use human error theory [referring specifically to RCA,
one aspect of human error theory] and educational
outreach in practice role plays before being let loose on
GPs! (Pharmacist 4, diary extract regarding training
session 4)
Pharmacists’ views on the other areas of the
training programme
The sessions on clinical research (in training session 1), along
with data analysis and interpretation (in training session 4),
were deemed too long by pharmacists and perhaps not spe-
cific enough for the trial’s objectives:
The clinical research section could possibly be shorter,
allowing more time for more relevant areas. (Pharma-
cist 5, evaluation feedback for training session 1)
Aim less at data quality facilitators and more at
us. (Pharmacist 2, evaluation feedback for training
session 4)
Likewise, in training session 2, where different GP clinical
computer systems were discussed, this was perceived as
useful but feedback indicated that pharmacists would have
found the session more useful if they had had the opportu-
nity to gain practical experience on the different clinical
systems:
It would have been more useful to have had practical
experience as at the moment it is hard to visualise what
the different systems are capable of. My concern is
when undertaking discussions with GPs I will not have
much idea of what their system is capable of and how
solutions may be sought. (Pharmacist 4, diary extract
regarding training session 2)
It would have been nice to have more interactive ses-
sions i.e. hands-on or exercises. (Pharmacist 1, evalua-
tion feedback for training session 2)
Whereas the training session on clinical codes (covered
in training session 3) was seen as useful, there were com-
ments that it was quite long and pharmacists questioned
whether they required this information in the depth that
was provided:
Read coding [a clinical coding system used in UK
general practice] will benefit me when I begin the
trial. (Pharmacist 1, evaluation feedback for training
session 3)
It was useful to have some background to Read/clini-
cal codes, though I’m not sure the whole day was
needed. (Pharmacist 4, diary extract regarding training
session 3)
Pharmacists commented that they would have preferred
more practical training in its place. This was particularly
apparent during the final training session (training session 5),
which was held at a local GP practice.
Improving the pharmacists’ training package
In terms of how the training package could be improved, the
overarching message from the pharmacists was that there
should have been more opportunities for hands-on practical
experience of working with the GP clinical systems. The
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opportunity to gain more practical experience on the GP
clinical systems was indicated by pharmacists throughout the
training sessions:
More hands on experience of EMIS [Egton Medical
Information System Limited, a primary care clinical
software programme) for those not familiar with
it. (Pharmacist 2, evaluation feedback for training
session 3)
It was very useful to have the chance of looking at
the computer. (Pharmacist 4, evaluation feedback for
training session 5)
IT training – possible inclusion of working software to
work through. (Pharmacist 6, evaluation feedback for
training session 4)
Pharmacists also expressed a desire to have more opportu-
nities to practise the concepts of educational outreach and
RCA in a role play scenario, as these were deemed to be the
most important aspects of the training package.
More role play opportunity possibly at the expense of
‘technical aspects’, e.g. data extraction etc. (Pharmacist
6, evaluation feedback for training session 4)
Discussion
Main findings
These findings would suggest that the training the pharma-
cists received, which included the principles of educational
outreach and RCA, resulted in the pharmacists feeling more
confident and competent in effectively delivering the trial
intervention to bring about change. The pharmacists also felt
the skills that they learned to deliver the PINCER interven-
tion would be beneficial in their pharmacist roles outside of
the PINCER Trial to deliver key prescribing information to
GPs and their practice staff.
Strengths and limitations
Overall, the training package used to deliver the intervention
was very thorough and consisted of well-thought-out train-
ing materials, with each component of the training package
being delivered by people with considerable knowledge and
experience in the area. The training provided also allowed the
PINCER pharmacists the opportunity to practise what they
had learned through role plays and ask questions.
The demographics of the pharmacists attending the train-
ing sessions also varied, with a range of professional experi-
ences within primary and secondary care settings, years
qualified and qualifications. All training sessions had full
attendance and were evaluated well by the pharmacists com-
pleting evaluation forms.
However, we acknowledge that there are some limitations
to this work. The training was delivered to only a small
number of pharmacists and could have been strengthened by
a greater number of pharmacists undergoing the training.
Although the evaluation forms were anonymous, due to the
small number of pharmacists attending the training session
they may have feared they would have been identified, possi-
bly eliciting a more positive evaluation of the training than
was the case. Feedback on the sessions was evaluated by the
research team as opposed to being evaluated independently
which would have made the evaluation more rigorous. Like-
wise, a more balanced five-point Likert scale would have been
preferable. However, due to the small number of participants,
a relatively simple three-point scale was chosen to indicate
levels of satisfaction with the training. In four of the six
training sessions data collection was incomplete, with three
pharmacists not completing an evaluation form and four
pharmacists not evaluating all the questions on the form.
Although we did not conduct a follow-up evaluation of the
training after intervention delivery, this was explored in the
PINCER Trial nested qualitative study.[28]
The evaluation of the training programme showed that the
pharmacists would have liked more time for role play and that
the generic elements were not tailored quite enough to the
intervention. We also acknowledge that time in general was a
limiting factor and this did mean we could not always go into
the depth we would have liked to. For example, it would have
been beneficial to have had more hands-on-time with the
clinical systems for those pharmacists not familiar with them.
Wider discussion
This training package was designed specifically for the
PINCER Trial, a robust randomised controlled trial that dem-
onstrated a statistically significant difference for each of the
three primary pharmaceutical indicators (outcomes) at the
main 6 month assessment in the pharmacy-led intervention
group of practices.[7] It could easily be shortened for wider
primary care pharmacy use, by excluding the topics specific to
the PINCER Trial (see Table 3). It is unlikely that excluding
the trial-specific elements would reduce the expected benefits
of the training as the most positive comments were in relation
to the generic topics. This would allow flexibility in the train-
ing package and help ease the time constraints that pharma-
cists often face. The evaluation of the training package
highlighted the fact that pharmacists believed receiving more
hands-on experience of the GP clinical systems and opportu-
nities to undertake more role play would have been useful and
this should be considered for future roll out.
On commencing the PINCER Trial, three of the PINCER
pharmacists were already working as primary care pharma-
cists, and so had prior knowledge and experience of how to
use GP clinical systems along with a general insight to how GP
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practices work. It is possible that having this expertise is
advantageous in undertaking this type of intervention but it
would appear that it is not imperative, as the results of the
PINCER Trial showed.[7]
Conclusions
The training evaluation showed that the use of the key princi-
ples of educational outreach combined with RCA resulted in
the pharmacists feeling more confident and competent in
effectively delivering the PINCER Trial intervention. It is
therefore possible that the provision of this type of training
could have a much wider application in helping pharmacists
have a more proactive day-to-day role in helping GP practices
identify key system failures in relation to prescribing safety
and in turn improve outcomes in a wide range of pharmaceu-
tical interventions. We suggest that these principles should be
incorporated into pharmacy practice, particularly in the
primary care setting. The future of the PCT primary care
pharmacist is changing and commissioning groups and
private companies who will be taking on this role will need to
think about the training needs and provision of training for
pharmacists delivering interventions in GP practices.
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Appendix 1 PINCER pharmacist training evaluation form
PINCER pharmacist training evaluation
To evaluate our training programme it would be of help if you could complete this evaluation form. The form is anonymous,
although we would like information about your professional background.
Please answer all questions by placing a tick in a box or by commenting in the space provided.
1. Please tick which best describes your professional background:
Academic researcher or lecturer  Community pharmacist 
Hospital pharmacist  PCT Pharmacist 
Other (please specify): 
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2. In terms of the pre-training information, how satisfied were you with:
dissatisfied satisfied very satisfied
a) the content of material sent?   
b) the timing of material sent?   
Comments:
3. How satisfied were you with these aspects of the training?
dissatisfied satisfied very satisfied
a) pre-training arrangements   
b) training materials/handouts   
c) venue/refreshments   
Comments:
4. To what extent did the training:
failed satisfied exceeded
a) match your expectations?   
b) meet the training objectives?   
c) help your understanding?   
d) contain sufficient detail and
examples?   
Comments:
5. Was the training:
not at all satisfactory very satisfactory
a) presented professionally?   
b) relevant?   
c) sufficiently interactive?   
Comments:
6. Was the pace of the training:
too slow about right too fast
  
Comments:
7. How could the training content and delivery be improved?
8. To what extent will this training help your future work?
9. Do you think you may have any future training or support needs relating to the topics covered today?
10. Do you have any other comments?
Please return the form to:
Dr Sarah Rodgers, Pincer Trial Co-ordinator, Division of Primary Care, 13th Floor, Tower Building, University Park,
Nottingham NG7 2RD
Thank you for taking the time to complete this evaluation.
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